Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852224 | 1.00 | SYK (0.44) | SYKBCHEACHECA1CA2 | |
| SCHEMBL4853723 | 0.92 | BCHE (0.44) | SYKBCHEACHEMAOB | |
| SCHEMBL4852212 | 0.92 | BCHE (0.44) | SYKBCHEACHEMAOB | |
| SCHEMBL4849917 | 0.91 | SYK (0.45) | SYKBCHEACHEABCG2MAOB | |
| SCHEMBL4857397 | 0.91 | SYK (0.45) | SYKBCHEACHEABCG2MAOB | |
| SCHEMBL4856235 | 0.91 | MAOA (0.46) | SYKBCHEACHEMAOB | |
| SCHEMBL6141442 | 0.91 | MAOA (0.46) | SYKBCHEACHEMAOB | |
| SCHEMBL4853732 | 0.91 | BCHE (0.54) | SYKBCHEACHESLC6A9 | |
| SCHEMBL4854231 | 0.91 | BCHE (0.54) | SYKBCHEACHESLC6A9 | |
| SCHEMBL4854085 | 0.90 | ABCG2 (0.51) | BCHEACHEABCG2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423181-B2 | in particular against bacterial and parasitic infections, fungi, and helminths; improved metabolic and physiochemical properties, bioavailability, solubility; 3-[4-(2-Dimethylamino-ethoxy)-2'-trifluoromethyl-biphenyl-3-yl]-1-(2-dimethylaminomethyl-phenyl)-propenone | LICA PHARMACEUTICALS A/S (DK) | 2008-09-09 | — | — | US | disclosed |
| US-20080027075-A1 | Quaternary Amino-Function Chalcones | LICA PHARMACEUTICALS A/S (DK) | 2008-01-31 | — | — | US | disclosed |
| US-20050227990-A1 | Aminoalkoxy-functional chalcones | LICA PHARMACEUTICALS A/S (DK) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027075-A1 | Quaternary Amino-Function Chalcones | NR2E1, BET1, NR0B1 | SYK 3108/4885BCHE 3286/4885ACHE 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.